SPAR Group (NASDAQ:SGRP) issued optimistic financial guidance for fiscal year 2026 on Tuesday, March 31, 2026, signaling a major turn toward higher profitability and operational efficiency.
Scholar Rock (NASDAQ:SRRK) announced on Tuesday, March 31, 2026, that it has officially resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for apitegromab.
SCYNEXIS (NASDAQ:SCYX) announced a transformative strategic shift on Tuesday, March 31, 2026, transitioning its core focus toward rare kidney diseases through a significant asset acquisition and a major equity financing.
AIRO Group Holdings (NASDAQ:AIRO) announced financial results for the fourth quarter and full year ended December 31, 2025, on Tuesday, highlighting significant double-digit revenue growth and a return to break-even profitability.
60 Degrees Pharmaceuticals (NASDAQ:SXTP) reported robust financial and operational results for the full year 2025 on Tuesday, March 31, 2026, headlined by a 65% surge in net product revenue.
MiNK Therapeutics (NASDAQ:INKT) reported its fourth-quarter and full-year 2025 financial results on Tuesday, detailing a well-capitalized path toward several major clinical readouts in the coming year.
Palvella Therapeutics (NASDAQ:PVLA) reported transformative full-year 2025 financial results and a significant corporate update on March 31, 2026, headlined by the successful clinical validation of its lead rare disease program.
BOS (NASDAQ:BOSC) reported record-breaking financial results for the full year 2025 on Tuesday, characterized by significant double-digit growth across all key profitability metrics.
Soligenix (NASDAQ:SNGX) reported financial results for the full year ended December 31, 2025, on March 31, 2026, emphasizing a clear pathway toward critical late-stage clinical data readouts.
Keenova Therapeutics (NYSE:MNK) reported robust fourth-quarter and full-year 2025 financial results on Tuesday, marking its first full quarter as a combined branded therapeutics entity following the merger of Mallinckrodt and Endo.
Eli Lilly and Company (NYSE:LLY) announced a definitive agreement on Tuesday to acquire Centessa Pharmaceuticals, marking a significant strategic entry into the sleep medicine market.
Xtant Medical Holdings (NYSE:XTNT) reported robust financial results for the full year 2025 on Tuesday, marked by double-digit revenue growth and a strategic pivot toward its core orthobiologics business.
